This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Grant & Eisenhofer Represents Whistleblower Accusing Celgene Corp. Of Off-Label Marketing Of High-Risk Cancer Drugs Derived From Thalidomide

Stocks in this article: CELG

LOS ANGELES and WASHINGTON, Feb. 6, 2014 /PRNewswire/ -- Leading whistleblower law firm Grant & Eisenhofer P.A. represents a key whistleblower in a false claims lawsuit unsealed today against one of the nation's largest pharmaceutical companies, Celgene Corporation (NASDAQ: CELG) involving charges of off-label marketing of two of its cancer treatment drugs.  

The federal suit alleges that Celgene marketed its drugs Thalomid and Revlimid to cancer patients and their doctors for unapproved purposes, and paid kickbacks to physicians for prescribing the medications. Thalomid is a form of thalidomide, a drug notorious for causing severe birth defects in the 1960s, making the term "thalidomide baby" a shorthand for a generation of birth abnormalities; its usage led Congress to strengthen FDA oversight of pharmaceuticals. The suit alleges that Celgene engaged in unlawful marketing schemes of both Thalomid and Revlimid, costing the U.S. government and state healthcare payors hundreds of millions of dollars.

Filed in U.S. District Court for the Central District of California, the suit, U.S. ex rel. Beverly Brown v. Celgene Corp., was originally filed under seal in 2007.  The lawsuit was brought under both federal and state false claims acts, as well as the California Insurance Frauds Prevention Act, which mandate initial filing under seal.

Grant & Eisenhofer is representing Beverly Brown , a former top-performing sales representative at Celgene who worked heavily on marketing both Thalomid and Revlimid during her decade-long stint at the company (2001-11).   

Ms. Brown's complaint alleges that Celgene preyed on a vulnerable patient population by aggressively marketing highly toxic drugs –Thalomid, and later Revlimid – for high-risk cancer treatments that had not been approved by the FDA. According to the suit, Celgene knowingly concealed the risks of venous thromboembolism and deaths associated with Thalomid use in cancer patients. The suit contends that when Celgene ultimately secured an indication for treatment of multiple myeloma with Thalomid, the approval was conditioned on a black-box warning on the drug's packaging, alerting doctors and patients of the significant risks of venous thromboembolism and fatality.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs